CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for NuRx Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

NuRx Pharmaceuticals Inc
18 Technology Dr Ste 130
Phone: (949) 336-7111p:949 336-7111 IRVINE, CA  92618-2310  United States Ticker: NUXP NUXP
On 9/22/2014, the U.S. Securities and Exchange Commission revoked the registration of each class of registered securities of NuRx Pharmaceuticals Inc. for failure to make required periodic filings with the Commission
This company is no longer actively traded on any major stock exchange.
Business Summary
NuRx Pharmaceuticals Inc. (NuRx) is an early stage research and development biopharmaceutical company with a focus on oncology products (leukemia and lung cancer). The Company is a development stage company and focused on the research and development activities in drug development activities and in prototype development for its lateral flow technologies through its QN Diagnostics, LLC (QN Diagnostics) joint venture. As of September 30, 2009, the Company had a single active clinical trial for its lead compound, NRX 5183 Phase II for Relapsed Acute Promyelocytic Leukemia (APL) being conducted in collaboration with Piramal Life Sciences, Limited (Piramal) at five sites in India with one patient enrolled.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20109/30/2009YesYes--Yes

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Director HarinPadma-Nathan 55 6/1/2007 5/31/2007
Chief Scientific Officer RoshChandraratna 63 7/2/2010 5/1/2007
Director SharyarBaradaran 42 1/1/2009 6/1/2007
Director KurtBrendlinger 50 1/1/2009 4/1/2007

Business Names
Business Name
NuRx Pharmaceuticals Inc
NuRx Pharmaceuticals Inc.
NuRx Pharmaceuticals, Inc.
NUXP
Quest Group International Inc.
Quest Group International, Inc.

General Information
Number of Employees: 3 (As of 9/30/2009)
Outstanding Shares: 23,444,234 (As of 8/19/2010)
Shareholders: 460
Stock Exchange: OTC
Federal Tax Id: 870681500
Email Address: info@nurxpharma.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023